Solid Tumor Cell Therapy Program News Today

Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.

Researchers have found a treatment that works on some patients and, more importantly, a tool that can predict when it is likely to succeed.

Distinguished leaders in immunology and translational oncology join to support the Company's scientific approachStrengthening the focus on solid tumors and progressing two programs towards the

Investegate announcements from Achilles Therapeutics PLC, Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board